Kidney cancer rates near Pfas factory in Lancashire flagged as 'major source of concern'

A data analysis covering two decades of cases in a small industrial district in north-west England points to a finding that worries local residents. According to the Guardian, kidney cancer diagnosis rates within roughly 10 km of a Pfas-producing factory at Thornton-Cleveleys in Lancashire have run 24% above the UK average.

Pfas — per- and polyfluoroalkyl substances, nicknamed "forever chemicals" — are a family of compounds used in rain jackets, non-stick pans, carpet treatments and firefighting foams that resist breakdown in the environment. Environmental epidemiologists have over the past decade published studies linking blood Pfas levels to certain cancers (notably kidney and testicular), thyroid disorders and lower birth weight.

The study cited by the Guardian was carried out by epidemiologists at Lancaster University. Using anonymised NHS Lancashire cancer registry data, the team compared every kidney cancer diagnosis around Thornton-Cleveleys between 2003 and 2023 with national figures. After adjusting for age, sex and socioeconomic status, the incidence rate in the study area was 15.2 per 100,000 people, compared with a UK average of 12.3.

Professor Hannah Sterling, who led the work, said the findings "are not enough to establish causation, but they carry a signal too clear to ignore". Sterling pointed to animal studies showing Pfas accumulation in kidney tissue, and argued the UK should tighten water and soil monitoring standards.

The chemicals company that operates the site, AGC Chemicals Europe, responded after publication. The company said production remains within all limits set by the Environment Agency, that drinking water Pfas levels around the plant have been measured below national thresholds for the past five years, and that it will commission an independent assessment of the academic findings. The firm also noted that production at Thornton-Cleveleys has been gradually shifted away from long-chain Pfas to shorter-chain alternatives.

An Environment Agency spokesperson said the existing Pfas monitoring programme was expanded in 2024 but that the agency has not yet evaluated the new epidemiological data. The UK's drinking-water limit for total Pfas is currently 0.5 μg/L — looser than the EU's 0.1 μg/L and far above the US Environmental Protection Agency's 4 ng/L limit for specific PFOA/PFOS compounds.

Local councillors and patient groups have called for a national screening programme. Kidney cancer caught at low stage has a five-year survival of more than 80%, but late detection drops the figure to 14%. Cheap urine tests and imaging screens would be a workable option for identified risk groups.

National health and environment experts say the findings have triggered a wider policy conversation. The European Union in late 2024 issued a draft restriction proposal that would ban most Pfas compounds; the UK is developing its own post-Brexit regulatory framework but has not yet released a comparable package.

The Lancashire case echoes a wider global debate. Major manufacturers including 3M, Chemours and Solvay have in recent years announced cuts to Pfas production; in the United States, the state of Minnesota reached a $10.3bn settlement with 3M. In Britain, the legal route for similar action remains largely untested.

The Guardian's report has put Pfas back on the British political agenda. The Department of Health has announced it will commission a comparative analysis of cancer-diagnosis data against the Lancaster work, with findings expected in late 2026. Until then, residents around Thornton-Cleveleys live with the gap between academic findings and corporate reassurance.